Trial Profile
Efficacy and Safety Evaluation of the Intralesional Recombinant Human Epidermal Growth Factor (rhEGF) in Subjects With Diabetic Foot Ulcer. Multicenter, Randomized, Double-blind, Placebo-controlled Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 19 Jun 2023
Price :
$35
*
At a glance
- Drugs Recombinant epidermal growth factor (Primary)
- Indications Diabetic foot ulcer
- Focus Therapeutic Use
- 14 Jun 2023 Status changed from not yet recruiting to active, no longer recruiting.
- 21 Jun 2016 Planned primary completion date changed from 1 Oct 2017 to 1 Dec 2017.
- 21 Jun 2016 Planned initiation date changed from 1 May 2016 to 1 Jan 2017.